TOKYO — Japanese companies such as Nikon and materials maker AGC plan to invest a total of over 100 billion yen ($675 million) by fiscal 2027 to boost production of stem cell-based and other cutting-edge drugs, an area where Japan trails the U.S. and Europe.
Regenerative medicines — a field that includes products used to re-create lost tissue, gene therapies and CAR T-cell cancer therapies — are expected to see strong growth.
